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Abstract
Background: This review addresses the strengths and weaknesses of 6 different prognostic
indices, published since the Radiation Therapy Oncology Group (RTOG) developed and validated
the widely used 3-tiered prognostic index known as recursive partitioning analysis (RPA) classes,
i.e. between 1997 and 2008. In addition, other analyses of prognostic factors in groups of patients,
which typically are underrepresented in large trials or databases, published in the same time period
are reviewed.
Methods: Based on a systematic literature search, studies with more than 20 patients were
included. The methods and results of prognostic factor analyses were extracted and compared. The
authors discuss why current data suggest a need for a more refined index than RPA.
Results: So far, none of the indices has been derived from analyses of all potential prognostic
factors. The 3 most recently published indices, including the RTOG's graded prognostic assessment
(GPA), all expanded from the primary 3-tiered RPA system to a 4-tiered system. The authors' own
data confirm the results of the RTOG GPA analysis and support further evaluation of this tool.
Conclusion: This review provides a basis for further refinement of the current prognostic indices
by identifying open questions regarding, e.g., performance of the ideal index, evaluation of new
candidate parameters, and separate analyses for different cancer types. Unusual primary tumors
and their potential differences in biology or unique treatment approaches are not well represented
in large pooled analyses.
Background
Prognostic indices might represent a useful tool in pallia-
tive cancer treatment. Estimation of a patient's prognosis
in terms of overall survival might allow for tailored treat-
ment, i.e. more aggressive approaches when these are
likely to impact on survival and focus on disease stabilisa-
tion, symptom control and toxicity minimization when
the disease is more advanced, or comorbidity limits the
tolerability of aggressive therapy. In addition, prognostic
indices might also be used as inclusion/exclusion criteria
for clinical trials and for comparison of results across dif-
ferent studies in relatively homogeneous patient groups.
Brain metastases continue to represent a formidable chal-
lenge in oncology [1-3]. With increasing numbers of local
and systemic treatment options, the issue of patient selec-
tion gains importance. While surgery and stereotactic radi-
osurgery (SRS) provide long-term local control of
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macroscopic disease and in combination with whole-
brain radiotherapy (WBRT) the best available overall
brain control for the remaining life time [4-10], they rep-
resent overtreatment in patients with short survival, which
typically is caused by uncontrollable systemic disease.
This review will address the strengths and weaknesses of 6
different prognostic indices, published since the Radia-
tion Therapy Oncology Group (RTOG) developed and
validated the widely used 3-tiered prognostic index
known as recursive partitioning analysis (RPA) classes
[11,12], i.e. between 1997 and 2008. In addition, other
analyses of prognostic factors in groups of patients, which
typically are underrepresented in large trials or databases,
published in the same time period are reviewed. These
include patients with primary tumors that do not com-
monly metastasize to the brain, and the elderly, who are
often either excluded or under-represented in clinical tri-
als.
Methods
The present review compares different prognostic indices
and analyses of prognostic factors based on a systematic
literature search by use of Medline (Pub Med by the
National Library of Medicine, National Institutes of
Health, Bethesda, Maryland, USA). It is limited to adult
patients having received first-line treatment for parenchy-
mal brain metastases in the absence of leptomeningeal
disease. The key words used were "brain metastases",
"metastatic brain tumor" and "cerebral metastases". The
final search was performed on June 30, 2008. It also
included the reference lists of all articles and the appropri-
ate chapters in textbooks on brain metastases, neuro-
oncology and radiation oncology. Case reports and review
articles were not assessed. Only studies with more than 20
patients were included. If several subsequent reports were
published from the same institution, the most recent pub-
lication was evaluated. The methods and results of prog-
nostic factor analyses were extracted and compared.
Results
The search identified 6 different prognostic indices, which
are shown in Table 1. Comparison of the patients' charac-
teristics is shown in Table 2. Unfortunately, a considera-
ble amount of information can not be extracted from the
publications. The most widely used index over the last
decade is the RPA index originally described by Gaspar et
al. on behalf of the RTOG [11], which is based on 4
parameters (age, Karnofsky performance status (KPS),
presence or absence of extracranial metastases, and the
control status of the primary tumor), separating patients
into 3 different classes. Lutterbach et al. suggested expan-
sion of the classification by further dividing class III into
3 separate classes [13]. This was based on their multivari-
ate analysis of 916 patients from a single institution, but
was not adopted by other authors in subsequent publica-
tions. Their definition yielded class IIIa defined as age <65
years, controlled primary tumor and single brain metasta-
sis, class IIIc defined as age ≥ 65 years, uncontrolled pri-
mary tumor and multiple brain metastases, while other
patients would make up class IIIb. The original RPA clas-
sification has been validated by several authors, both in
selected and unselected patient groups, e.g., patients with
breast primary, lung primary (small cell and non-small
cell), malignant melanoma, unknown primary, or surgi-
cal resection and SRS as main local treatment modalities
[14-35].
Probably, the surgically treated patients represent the
most homogeneous cohorts assessed with the RPA sys-
tem, as these were patients with rather favourable progno-
sis, fit to undergo surgery and with limited brain disease.
Nevertheless, the differences in median survival between
the individual studies were large. In RPA class I, median
survival ranged from 15–29 months [31-35]. In class II, a
survival range of 5.5–11 months has been reported. In
class III, these figures reached 1.4–9 months. As illustrated
here, survival within the same RPA class might vary by a
factor of 2 or more between different studies (identical
treatment approach). In series where the majority of
patients were treated with WBRT, less variation between
studies can be found (Figure 1). As shown in Table 1, both
RPA class II and III contain quite heterogeneous groups of
patients. The factor determining class III is KPS<70, which
might result from many different causes including the
brain metastases themselves, advanced and treatment-
refractory extracranial metastases, severe pain or patho-
logical fracture in patients with bone metastases, atelecta-
sis or pneumonia from primary lung cancer, anemia
induced by chemotherapy, recovery from recent surgery,
and non-cancer-related comorbidity. In all the reports
reviewed variable proportions of patients in the most
favourable RPA class I unexpectedly died within 2
months, while some patients in class III survived for more
than 6 months. For these reasons, there obviously is a
need for a more refined index than RPA.
The first attempt in 1999 resulted in the Rotterdam Score,
which did not gain wider acceptance [36]. Similar to RPA,
performance status and extent of systemic disease were
included, while the third parameter was response to ster-
oids before WBRT. It can be assumed that the unavailabil-
ity of this latter parameter in most databases or patient
records prevented other groups from using the score. In
addition, the definition of systemic tumor activity is not
straight forward. The next attempt (Score Index for Radio-
surgery (SIR)) was derived from a limited number of
patients treated with this particular focal approach, which
might have resulted in overfitting of the data [37]. How-
ever, several groups confirmed the performance of the SIR
in patients treated with SRS, surgery, and WBRT with orR
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Table 1: Comparison of the prognostic scores published since 1997, empty fields indicate that a parameter is not used in the index
Score Performanc
e status
Age Extracranial 
metastases
Controlled 
primary
Steroid 
treatment
Number of 
BM
Volume of 
BM
Interval to 
BM
Class I Class II Class III Class IV
RPA11
Derived 
from 3 
prospective 
RTOG 
studies, 
n = 1,200
KPS
≥ 70 vs <70
<65 years no vs yes no vs yes all 4 
favourable 
factors
other 
patients
KPS <70 none
Rotterdam36
Single 
institution, 
n = 1,292
ECOG
0–1 vs 2–3
limited 
activity vs
systemic 
extensive*
good, 
moderate 
or little 
response
ECOG 0–1 
with no or 
limited 
systemic 
tumor 
activity and 
good 
response to 
steroids
other 
patients
ECOG2-3 
with limited 
or extensive 
systemic 
activity and 
little 
response to 
steroids
none
SIR37
Single 
institution, 
n = 65
KPS 80–
100:2 points
KPS 60–70: 
1 point
KPS ≤ 50: 0 
points
≤ 50: 2 
points
51–59: 1 
point
≥ 60: 0 
points
no evidence 
of systemic 
disease or 
complete 
remission: 2 
points
partial 
remission or 
stable
disease: 1 
point
progressive 
disease: 0 
points
1: 2 points
2: 1 point
≥ 3: 0 points
largest 
lesion 
volume <5 
cc: 2 points
5–13 cc: 1 
point
>13 cc: 0 
points
8–10 points 4–7 points 1–3 points none
BSBM43
Single 
institution, 
n = 110
KPS 80–100: 
1 point
KPS ≤ 70: 0 
point
no: 1 point
yes: 0 points
yes: 1 point
no: 0 points
3 points 2 points 1 point 0 points
GPA44
Derived 
from 5 
prospective 
RTOG 
studies, 
n = 1,960
KPS 90–100: 
1 point
KPS 70–80: 
0.5 points
KPS <70: 0 
points
<50: 1 point
50–59: 0.5 
points
>60: 0 
points
none: 1 
point
present: 0 
points
1: 1 point
2–3: 0.5 
points
>3: 0 points
3.5–4 points 3 points 1.5–2.5 
points
0–1 points
Rades et 
al.45
Multi-
institutional, 
n = 1,085
KPS ≥ 70: 5 
points
KPS <70: 1 
point
≤ 60: 4 
points
>60: 3 
points
none: 5 
points
present: 2 
points
>8 mo: 4 
points
≤ 8 mo:
3 points
17–18 
points
14–16 
points
11–13 
points
9–10 points
BM: brain metastases, RPA: recursive partitioning analysis, RTOG: Radiation Therapy Oncology Group, KPS: Karnofsky performance score, SIR: score index for radiosurgery, BSBM: basic score 
for brain metastases, GPA: graded prognostic assessment, ECOG: Eastern Cooperative Oncology Group
* limited systemic activity: no systemic metastases but progression of primary tumor or systemic metastases with primary tumor absent or controlled; extensive systemic activity: systemic 
metastases and progressive primaryRadiation Oncology 2009, 4:10 http://www.ro-journal.com/content/4/1/10
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without SRS, some of them with large numbers of patients
(Figure 2) [35,38-44]. To accurately define systemic dis-
ease activity, comprehensive diagnostic work-up is
needed.
When evaluating the SIR and RPA indices in their SRS
database, the group from Brussels, Belgium, arrived at a
new score, which they called Basic Score for Brain Metas-
tases (BSBM) [43]. Based on its greater convenience and
simplicity, they advocated the use of this score, which uses
the same definition of extracranial disease activity as the
RTOG. Recent data indicate that BSBM can be applied to
patients managed with WBRT with or without SRS and
surgery plus WBRT [35,42,44], however its performance is
not better than that of the other scores (Figure 3).
The RTOG has recently proposed a new index, which was
compared to RPA, SIR, and BSBM (but not to the Rotter-
dam score) [44]. The new score (Graded Prognostic
Assessment (GPA)) is different from RTOG's RPA, e.g.,
with regard to the number of prognostic classes, which
increased from 3 to 4, and the larger number of patients.
The analysis also includes patients managed with WBRT
plus SRS from RTOG study 9508 [5]. In the GPA system,
Table 2: Median values of reported patients' characteristics in each of the studies, empty fields indicate missing information
Score Performance 
status
Age Extracranial 
metastases
Controlled 
primary
Steroid 
treatment
Number of 
BM
Volume of 
BM
Interval to 
BM
RPA11
n = 1,200
KPS 70 55–59 yrs. 
range
38% 60% 2
Rotterdam36
n = 1,292
ECOG 1 59 yrs. mean 15 mg 
dexamethason
e per day
2 8.5 mo.
SIR37
n = 65
KPS 80 61 yrs. 2 3.3 cc
BSBM43
n = 110
57 yrs. 2 9 cc
GPA44
n = 1,960
KPS 80 60 yrs. 36% 67% 2 5–13 cc
Rades et al.45
n = 1,085
KPS 70 60 yrs. 64% 8 mo.
BM: brain metastases, RPA: recursive partitioning analysis, KPS: Karnofsky performance score, SIR: score index for radiosurgery, BSBM: basic score 
for brain metastases, GPA: graded prognostic assessment, ECOG: Eastern Cooperative Oncology Group
Comparison of median survival in 7 studies using the recursive partitioning analyses (RPA) classes (treatment was WBRT with  or without local measures, none of the studies is limited to one particular cancer type) Figure 1
Comparison of median survival in 7 studies using the recursive partitioning analyses (RPA) classes (treatment 
was WBRT with or without local measures, none of the studies is limited to one particular cancer type).
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3 different values (0, 0.5 or 1) are assigned for each of
these 4 parameters: age (≥ 60; 50–59; <50), KPS (<70; 70–
80; 90–100), number of brain metastases (>3; 2–3; 1),
and extracranial metastases (present; not applicable;
none). Assessment of primary tumor activity or control is
no longer mandated. It was concluded by the authors that
"GPA is the least subjective, most quantitative and easiest
to use of the 4 indices" and that future trials should com-
pare these scores and validate the GPA. One of the
authors' group has embarked on this comparison in 2 dif-
Comparison of median survival in 2 studies using the score index for radiosurgery (SIR) (treatment was WBRT with or without  local measures, studies not limited to one particular cancer type) Figure 2
Comparison of median survival in 2 studies using the score index for radiosurgery (SIR) (treatment was WBRT 
with or without local measures, studies not limited to one particular cancer type).
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Comparison of median survival in 2 studies using the basic score for brain metastases (BSBM) (treatment was WBRT with or  without local measures, studies not limited to one particular cancer type) Figure 3
Comparison of median survival in 2 studies using the basic score for brain metastases (BSBM) (treatment was 
WBRT with or without local measures, studies not limited to one particular cancer type).
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ferent patient populations, i.e. those managed with WBRT
with or without SRS (comparable to the RTOG study pop-
ulation) [42] and those managed with surgery and WBRT
[35]. Both studies basically relied on the methods used by
the RTOG in their analysis, though with patients treated in
clinical routine outside of randomized trials. Compared
to RTOG's patients treated with WBRT with or without
SRS, the median age, KPS, number of lesions and lesion
volume were similar. Obvious differences existed, how-
ever, regarding controlled primary tumor (47 vs. 67%)
and extracranial metastases (56 vs. 36%). Thus, the cohort
is expected to have inferior survival. Figure 4 shows the
survival results.
Last but not least, Rades et al. developed a new prognostic
index based on 4 parameters (age, KPS, extracranial
metastases at the time of WBRT, interval from tumor diag-
nosis to WBRT) [45]. The major difference from the RPA
classes is the replacement of primary tumor control by
interval from tumor diagnosis to WBRT (not by number
of brain metastases as in the GPA). This index separated
patients into 4 subgroups with significantly different
prognosis and was also validated in one of the authors'
database (unpublished results, Figure 5).
Discussion
As stated on the website of the National Cancer Institute
http://www.cancer.gov/templates/
bd_alpha.aspx?CdrID=44246, a prognostic factor is
regarded as a situation or condition, or a characteristic of
a patient, that can be used to estimate the chance of recov-
ery from a disease or the chance of the disease recurring.
Based on such prognostic factors, 6 different prognostic
indices for adult patients with brain metastases from solid
tumors have been developed over the last decade. As dem-
onstrated in Table 1, the 3 most recently published indices
all expanded from the primary 3-tiered RPA system to a 4-
tiered system. The 6 indices are based on a different
number of prognostic factors, i.e. 3–6. Of course, increas-
ing numbers of parameters will lead to less convenience
and ease of administration. None of the groups that devel-
oped these indices included all potential prognostic fac-
tors in their analysis. This is most likely due to the
unavailability of all the information in the databases and
the difficulty in collecting missing data in 1,000 or more
patients treated over many years. As can be seen in Figures
3, 4, 5, the performance of the 4-tiered indices is not tre-
mendously different, although further data are needed to
confirm this finding.
There is agreement in all indices on the importance of per-
formance status and extracranial disease activity. How-
ever, whether both primary tumor and extracranial
metastases should be considered is less clear (2 indices
would not include primary tumor control). Assessment of
extracranial disease status is not trivial. It might require
considerable resources in patients with very limited life
expectancy and therapeutic options. When collecting data
over long time periods, one must expect a shift in diagnos-
tic modalities, i.e. increasing use of magnetic resonance
Comparison of median survival in 2 studies using the graded prognostic assessment (GPA) (treatment was WBRT with or  without local measures, studies not limited to one particular cancer type) Figure 4
Comparison of median survival in 2 studies using the graded prognostic assessment (GPA) (treatment was 
WBRT with or without local measures, studies not limited to one particular cancer type).
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imaging of the brain as compared to computed tomogra-
phy (CT) or increasing use of chest CT or even positron
emission tomography (PET). Such a shift will likely result
in no longer assigning patients to the most favourable
prognostic class (stage migration). This might compro-
mise the comparison of the different studies.
Two of the 6 indices did not include age and the ones that
did, used slightly different cut-off values. A minority of stud-
ies (n = 2) included number of brain metastases and only
one each included response to steroids, volume of the largest
lesion in the brain, and time interval to development of
brain metastases, respectively. Other previous reports lend
credence to the examination of each of these factors. In their
multivariate analysis of 334 patients, DiLuna et al. reported
significantly better survival in patients with 1–3 vs 4 or more
brain metastases and in those patients with both limited
number and volume of brain metastases (<5 cc total vol-
ume) [46]. Bhatnagar et al. also reported on the impact of
treatment volume as independent prognostic factor in
patients treated with SRS [47]. In a randomised trial with
544 patients, Priestman et al. found that dose of steroids was
independently associated with survival [48]. Interval to
development of brain metastases appears particularly impor-
tant in patients with primary NSCLC and malignant
melanoma. The multivariate analyses of 3 studies with 292–
686 patients support this observation [23,49,50].
The latter findings lead to the general question on the use-
fulness of lumping together patients with different primary
tumors in these models. Breast cancer poses an interesting
dilemma here, because although tumor type and histology
were not prognostically significant in the RPA, recent data,
especially since the advent of trastuzumab and lapatinib,
suggest that, receptor status and her-2-neu expression
might have prognostic impact, even if this issue is not with-
out controversy (Table 3). The recently suggested prognos-
tic factor lymphopenia falls into the same category [19,51].
Unusual primary tumors and their potential differences in
biology or unique treatment approaches are not well repre-
sented in large pooled analyses. Table 4 provides examples
on analyses of prognostic factors in such groups.
Surrogate markers of disease activity that are easy to meas-
ure and inexpensive, such as lactate dehydrogenase and
other laboratory parameters have repeatedly been shown
to be independent prognostic factors for survival [71-74].
Studies that were not limited to patients with brain metas-
tases suggest that the anorexia-cachexia syndrome, dysp-
nea, pain, and co-morbidity are further candidates for
prospective evaluation [74]. The same holds true for neu-
rofunction class [75,76] and mini mental status examina-
tion results, which was an independent prognostic factor
for survival in a multivariate model that also included KPS
[77]. The current prognostic indices unfortunately do not
incorporate these features.
One of the purposes of prognostic indices is to guide the
choice of treatment in individual patients. In this context,
a prognostic index should be accurate enough to avoid
Comparison of median survival in 2 studies using the index proposed by Rades et al Figure 5
Comparison of median survival in 2 studies using the index proposed by Rades et al. [45](treatment was WBRT 
with or without local measures, studies not limited to one particular cancer type, median survival estimated 
from the Kaplan-Meier curves in the publication).
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overtreatment in patients that actually have very short sur-
vival. Even more important, one should not withhold
treatment because the index erroneously predicts an unfa-
vorable outcome. These aspects of the indices have not
been thoroughly evaluated, even in the recent GPA analy-
sis [44]. In our analysis of 239 patients, which confirms
that RPA, SIR, BSBM and GPA each split the dataset into
groups with significantly different prognosis, this issue
was addressed [42]. With regard to the outcome of
patients with unfavorable survival, defined as ≤ 2 months
(n = 93), no significant difference between the indices was
observed. Regarding patients with favorable survival,
defined as ≥ 6 months (n = 66), again no significant dif-
ference was observed, although RPA performed worse
than the other indices. Overall, GPA misassigned 6% of
the patients (9 out of 159), compared to 11% with RPA.
Therefore, the available validation data certainly do not
discourage further evaluation of the new GPA. However,
such evaluation should also include comparison with the
2 other scores (Rotterdam and Rades et al.). It is just the
stark reality of the disease process that in all of the scoring
systems, the most favorable prognostic group is very small
(e.g., GPA ≥ 3.5: 9% of RTOG and 7% of our own patients;
RPA class I: 16% of RTOG and 11% of our own patients).
The open questions after publication of 6 prognostic indi-
ces include:
- how should the ideal index perform?
- how many parameters should form the basis of the
ideal index?
- can we lump together patients with breast cancer,
small-cell lung cancer, malignant melanoma etc. or do
we lose potentially important information?
- do we need candidate parameters beyond the ones
examined so far (lactate dehydrogenase, anemia,
weight loss, pain etc.)?
Table 3: Prognostic impact of hormone receptor and HER-2 status in patients with brain metastases from breast cancer
n Prognostic impact of hormone receptor status Prognostic impact of HER-2 status
Claude et al.51 120 none not examined
Bartsch et al.52 174 none None
Le Scodan et al.19 117 receptor negative significantly worse None
Nam et al.53 126 receptor negative significantly worse HER-2 negative significantly worse
Kirsch et al.54 95 not examined HER-2 negative significantly worse*
Eichler et al.55 83 none HER-2 negative significantly worse^
Melisko et al.56 112 receptor negative significantly worse none
Harputluoglu et al.57 144 none none
Park et al.58 125 none HER-2 positive significantly worse
Church et al.59 86 not examined HER-2 negative significantly worse*
^80% of HER-2 overexpressing cases received trastuzumab after diagnosis of brain metastases
* the difference in survival was limited to patients with HER-2 overexpressing cancer treated with trastuzumab after diagnosis of brain metastases
Table 4: Prognostic factors in patients underrepresented in large studies (minimum number of patients n = 20)
Author Population Significant prognostic factors
Ogawa et al.60 esophageal cancer, n = 36 KPS, aggressive local treatment (multivariate)
Weinberg et al.61 esophageal cancer, n = 27 no liver metastases, RPA class I (trend, p = 0.1, multivariate)
Khuntia et al.62 esophageal cancer, n = 27 KPS, aggressive local treatment (multivariate)
Cohen et al.63 ovarian cancer, n = 72 aggressive local treatment
Cormio et al.64 ovarian cancer, n = 22 extracranial disease, time to development of brain metastases
Growdon et al.65 gynaecological cancers, n = 30 extracranial disease, histology, use of chemotherapy (multivariate)
Tremont-Lukats et al.66 prostate cancer, n = 103 adenocarcinoma vs other histology
Rades et al.24 unknown primary, n = 101 KPS, extracranial metastases, RPA class
Bartelt and Lutterbach67 unknown primary, n = 47 KPS, surgical resection status (multivariate)
Ruda et al.68 unknown primary, n = 33 number of brain metastases (multivariate)
Kim et al.69 patients ≥ 75 years, SRS treatment, n = 44 single brain metastasis, NSCLC vs other primary
Noel et al.70 patients ≥ 65 years, SRS treatment, n = 117 KPS (multivariate)
WBRT: whole-brain radiotherapy, KPS: Karnofsky performance status, RPA: recursive partitioning analysis, SRS: stereotactic radiosurgery, NSCLC: 
non-small cell lung cancerRadiation Oncology 2009, 4:10 http://www.ro-journal.com/content/4/1/10
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- is it justifiable to assign the same point value to dif-
ferent degrees of extracranial disease, e.g., 2 small
asymptomatic lung metastases, 8 large liver metastases
with increased bilirubin, skin metastases already
treated by radiotherapy etc.?
- can international groups collaborate to develop a
consensus score, or maybe even an online tool?
Other aspects of predicting the outcome in patients with
brain metastases that many clinicians might appreciate,
relate to the important issue of neurologic function and
quality of life. In many instances, radiotherapy aims more
on improving deficits and preventing neurologic decline
than prolonging survival, but no attempts have been
made to develop scores that address endpoints other than
overall survival. It appears therefore worthwhile to collect
data on such endpoints, as done, e.g., in the recently com-
pleted randomized trial of radiotherapy with or without
motexafin gadolinium [78], which used time to neuro-
logic progression as primary endpoint. Other opportuni-
ties for future research include examination of prognostic
models that provide estimates on both risk of systemic
cancer progression with death from non-neurologic
causes and risk of death from uncontrolled brain metas-
tases.
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